Deutsche Märkte öffnen in 1 Stunde 21 Minute

TG Therapeutics, Inc. (TGTX)

NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
50,18-0,01 (-0,02%)
Börsenschluss: 4:00PM EST

TG Therapeutics, Inc.

2 Gansevoort Street
9th Floor
New York, NY 10014
United States
212 554 4484
http://www.tgtherapeutics.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter217

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Michael S. WeissCEO & Pres827,54kN/A1966
Mr. Sean A. Power CPA, CPACFO, Corp. Sec. & Treasurer470,56kN/A1982
Dr. Owen A. O'ConnorChief Scientific OfficerN/AN/AN/A
Jenna BoscoVP of Investor Relations & Sr. VP of Corp. CommunicationsN/AN/AN/A
Mr. Adam WaldmanChief Commercial OfficerN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2019 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL); and Ublituximab, an investigational glycoengineered monoclonal antibody that targets a epitope on CD20-expressing B cells for patients with NHL, CLL, and relapsing forms of multiple sclerosis. In addition, the company develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. It is also has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. is headquartered in New York, New York.

Corporate Governance

TG Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Dezember 2020, lautet 10. Die grundlegenden Scores sind Audit: 2, Vorstand: 10, Shareholderrechte: 4, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.